Vismodegib is useful to treat locally advanced or metastatic basal cell carcinomas (BCCs),1 but to our knowledge, its use as a neoadjuvant to shrink BCCs before surgery has not been reported. This case illustrates the role of vismodegib as a neoadjuvant agent. In addition, this case highlights the fact that a patient with Gorlin syndrome can develop resistant BCCs while taking vismodegib, a phenomenon not widely recognized although recently reported.2
Register and get free email Table of Contents alerts, saved searches, PowerPoint downloads, CME quizzes, and more
Subscribe for full-text access to content from 1998 forward and a host of useful features
Activate your current subscription (AMA members and current subscribers)
Purchase Online Access to this article for 24 hours
Figure 1. Clinical and computed tomographic (CT) images of a 55-year old man with Gorlin syndrome. The patient's locally advanced basal cell carcinoma (BCC) regressed under treatment with neoadjuvant vismodegib but demonstrated areas of drug resistance. Residual BCC and resistant areas were excised. A, Locally advanced BCC on the right scalp prior to treatment. B, Tumor shrinkage after 51 weeks of vismodegib therapy showing development of 2 areas of resistant BCC (arrowheads). C, After surgical excision, the patient received full-thickness skin grafts to cover the right scalp and the right tragus/external auditory canal, shown here at 2 months after surgery. D, Pretreatment axial CT image shows bony defects of the calvarium under the BCC. E, Posttreatment CT scan shows shrinkage of the calvarial defect after vismodegib therapy.
Figure 2. Vismodegib-resistant basal cell carcinoma (BCC) tumors (hBCCSmos) show increased levels of Gli transcription factors and pik3c (phosphatidylinositol 3-kinase catalytic) enzymes. Tumor hBCCSmoR1 was on the tragus and hBCCSmoR2 was on the posterior scalp. A, Compared with normal skin from the same patient, both resistant tumors showed elevation of pik3c (isoform 2a) level. Tumor hBCCSmoR2 showed elevations of Gli1, ptch1 protein, and all isoforms of pik3c levels. Analysis was undertaken by quantitative reverse-transcriptase polymerase chain reaction (qRT-PCR) performed in triplicate (RNeasy Mini Kit; Qiagen). Transcripts were quantified in triplicate using Brilliant II SYBR Green qRT-PCR Master Mix Kit (Agilent Technologies) with primers to human GLI1,4PTCH1,4 and PIK3C isoforms.5 B, Immunofluorescence analysis performed on formalin-fixed, paraffin-embedded tissue shows that Gli1 protein levels are elevated in tumor hBCCSmoR2 but not in hBCCSmoR1 compared with normal skin from the same patient. The top row of images depicts tissues viewed without fluorescence; the bottom row of images depicts tissues viewed with fluorescence. Immunofluorescence studies were performed with anti-Gli1 (1:500; Cell Signaling) and Hoechst 33342 (1:10 000; Invitrogen). Confocal images were acquired on a Leica SP2 AOBS Laser Scanning Microscope with an HCX PL APO 63X oil-immersion objective.
Thank you for submitting a comment on this article. It will be reviewed by JAMA Dermatology editors. You will be notified when your comment has been published. Comments should not exceed 500 words of text and 10 references.
Do not submit personal medical questions or information that could identify a specific patient, questions about a particular case, or general inquiries to an author. Only content that has not been published, posted, or submitted elsewhere should be submitted. By submitting this Comment, you and any coauthors transfer copyright to the journal if your Comment is posted.
* = Required Field
Disclosure of Any Conflicts of Interest*
Indicate all relevant conflicts of interest of each author below, including all relevant financial interests, activities, and relationships within the past 3 years including, but not limited to, employment, affiliation, grants or funding, consultancies, honoraria or payment, speakers’ bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued. If all authors have none, check "No potential conflicts or relevant financial interests" in the box below. Please also indicate any funding received in support of this work. The information will be posted with your response.
Some tools below are only available to our subscribers or users with an online account.
Download citation file:
Web of Science® Times Cited: 4
Customize your page view by dragging & repositioning the boxes below.
More Listings atJAMACareerCenter.com >
and access these and other features:
Enter your username and email address. We'll send you a link to reset your password.
Enter your username and email address. We'll send instructions on how to reset your password to the email address we have on record.
Athens and Shibboleth are access management services that provide single sign-on to protected resources. They replace the multiple user names and passwords necessary to access subscription-based content with a single user name and password that can be entered once per session. It operates independently of a user's location or IP address. If your institution uses Athens or Shibboleth authentication, please contact your site administrator to receive your user name and password.